Proxima Therapeutics Partners With Nucletron B.V. To Introduce MammoSite Therapy For Breast Cancer In Australia And New Zealand
10/19/2005 5:12:21 PM
Proxima Therapeutics today announced that Nucletron will be the exclusive distributor of the MammoSite Radiation Therapy System in Australia and New Zealand. MammoSite was developed by Proxima and cleared by the United States Food and Drug Administration (FDA) in May 2002 and received Australian Registration in June 2003. With this partnership, a five-day treatment regimen of partial breast irradiation with MammoSite will now be available to more than 11,000 women diagnosed with breast cancer each year in Australia and New Zealand.
comments powered by